



Demographic and Clinical Profile of Vernal Keratoconjunctivitis at A Tertiary Eye Care Center in India.

Manju J. Loya

Resident of Ophtalmology, Dr. VMGMC, Solapur.

Lokesh KC

Dr. VMGMC, Solapur.

Pranay Gandhi

Assistant professor in the Dept of community medicine, DY Patil medical college, Kolhapur.

ABSTRACT

Purpose: To study the demographic and clinical profile of patients with vernal keratoconjunctivitis (VKC) at a tertiary eye care center in India.

Materials and Methods: Retrospective chart analysis of 468 patients of VKC seen from January 2006 to December 2006.

Results: Mean age at presentation was 12 years. Majority of the patients had mixed pattern disease (72%). Chronic perennial disease was seen in 36% patients. Personal or family history of allergies was noted in 5% patients. Severe disease based on clinical grading was present in 37% patients. Moderate to severe vision loss was seen in 12% of total population. Persistent disease beyond 20 years of age was found in 12% patients. VKC-related complications such as corneal scarring (11%), shield ulcer (3%), keratoconus (6%), and limbal stem cell deficiency (1.2%) were seen. Treatment-related complications like corticosteroid-induced cataract and glaucoma were seen in 6% and 4% of patients, respectively.

Conclusion: Clinical pattern of VKC seen in the tropical climate of India is essentially similar to that seen in other tropical countries. Few distinct features that we noted represent chronic perennial disease, low association with atopy, and higher propensity for disease and treatment-related complications.

KEYWORDS : Allergic eye disease, papillae, shield ulcer, vernal keratoconjunctivitis

Vernal keratoconjunctivitis (VKC) is an allergic disease that typically affects young individuals with male preponderance.[1,2] Greater prevalence of VKC is seen in the regions with hot, humid climate, and higher load of airborne allergens. It is a common ocular surface disorder in the Mediterranean region, central Africa, India, and South America.[1,2,3,4,5,6,7] Clinically, it is characterized by presence of papillary hypertrophy of the palpebral and/or the limbal conjunctiva, bulbar conjunctival pigmentation, limbal thickening, Horner Trantas dots, and mucous discharge. Patients with VKC experience significant morbidity, which affects the quality of life;[8] moreover, vision-threatening corneal complication in severe and chronic cases coupled with potential iatrogenic side effects makes VKC a concerning ocular surface disorder.

The clinical profile of this disease seems to have geographical variations.[2,3,4,5,6,7] However, there are no major series explaining the demographic and clinical pattern of VKC from this part of the world; hence, we conducted a retrospective chart analysis to study the pattern of VKC in a tertiary eye care center in southern India.

Materials and Methods

A retrospective chart analysis of all patients of VKC who presented to our Tertiary Eye Care Institute in South India from January 2012 to December 2014 was done. A total of 468 VKC patients were identified. The diagnosis of VKC was made on the basis of history and typical signs and symptoms. Active VKC was diagnosed based on the complaint of ocular itching in the presence of upper tarsal conjunctival papillae and/or limbal hypertrophy with bulbar conjunctival pigmentation.[1] The severity of the disease was retrospectively graded based on the clinical signs at initial presentation, as per the method described by Bonini *et al.*[9] Visual impairment was assessed by means of the World Health Organization criteria for visual disabilities as used by Tabbara *et al.*[5]

Results

A total of 468 patients of VKC presented in the year 2012. Month-wise distribution showed highest number (71; 15%) of the patients in the month of May. The mean age at presentation was 12 years \pm 6.63 years (\pm Standard Deviation). There were 405 (87%) males and 63 (13%) females. The male (M) to female (F) ratio was 6.4:1. The male to female ratio increased with age and was 8.7:1 in patients aged >16 years. The disease was active at initial presentation in 393 individuals (84%). The average period between the initial onset of

symptoms and presentation to this institute was 25 ± 33 months (Mean \pm SD). Patients who had their first episode at or after 20 years of age were categorized as adult onset VKC. Fifty-six patients (12%) were aged ≥ 20 years at the time of presentation, of which 16 (14 males, 2 females) patients had an adult onset of disease, while the rest had primarily a childhood disease that continued beyond 20 years of age.

The common reported symptoms were itching (88%), redness (86%), and watering (65%). The commonest signs were palpebral papillae (85%) and limbal thickening (73%). Perilimbalconjunctival pigmentation was present in 52/468 (11%) of patients. Chronic perennial form of VKC, lasting for more than 48 months was present in 167 patients (36%). Isolated limbal form of VKC was present in 59 patients (12.6%), while isolated palpebral form was seen in 73 patients (15.6%). The majority (336; 72%) of patients had a mixed form of disease with involvement of both limbal and palpebral areas. The socio-economic status based distribution of these patients showed that 314 patients (67%) belonged to high socioeconomic group, while 154 patients (32%) belonged to low socioeconomic group. The criteria for low and high socioeconomic status were based on the nonpaying and paying categories of the patients, respectively.

In the present series, 23 patients (5%) had either a positive family or personal history of atopy or allergic disorders, of which 3 had positive family history and 20 had a personal history of allergic diseases that included respiratory tract-related allergies in 15 (variably termed as "dust allergy," rhinitis, bronchitis, and asthma by patients) and allergic dermatitis in 5 patients.

The categorical distribution based on severity of disease is shown in Table 1. At presentation, 119/468 (25%) patients were on topical corticosteroids, while information about topical corticosteroids use was not available in 31/468 (6%) patients. It is noteworthy that treatment at presentation could have altered the disease severity and may not represent the true clinical spectrum. We had 412 (88%) patients with visual acuity ranging between 20/20 to 20/50 (grade A: Mild visual loss), 39 (8%) patients with visual acuity ranging between 20/50 to 20/200 (grade B: Moderate visual loss), and 17 (4%) patients with visual acuity of 20/200 or less in the worse eye (grade C: Severe visual loss) [Table 2].

Table 1
Severity of vernal keratoconjunctivitis at presentation as per the grading system by Bonini *et al.*

Severity	Frequencies (%)
0	57 (12.17)
1	107 (22.86)
2A	68 (14.52)
2B	63 (13.46)
3	90 (19.23)
4	60 (12.82)
5	23 (4.91)

Table 2
Visual status of vernal keratoconjunctivitis patients at presentation

Category	Visual acuity	Number (%)
A	20/20 to 20/50	412 (88.03)
B	20/50 to 20/200	39 (8.33)
C (Economic blindness)	20/200 or less	17 (3.63)

The different ocular complications due to VKC seen in our series are described in [Table 3]. The commonest complication was corneal scarring, which was present in 52 patients (11%). Keratoconus was seen in 6%, whereas corneal shield ulcers were seen in 3% patients. Peripheral corneal neovascularization was seen in 34 (7%) patients. Clinically limbal stem cell deficiency (LSCD) (corneal neovascularization along with conjunctivalization and corneal scarring) was seen in 1.2% of patients. Corticosteroid-induced complications like cataract and glaucoma were seen in 6% and 4% of patients, respectively.

Table 3
Complications in vernal keratoconjunctivitis

Complications	Number of patients (%)
Total no. of patients	468
Corneal scar	52 (11.11)
Conjunctivalization of cornea/ Limbal stem cell deficiency	6 (1.2)
Shield ulcers	14 (2.99)
Keratoconus	29 (6.19)
Microbial keratitis	2 (0.42)
Dellen	1 (0.21)
Cataract	29 (6.19)
Glaucoma	18 (3.84)
Acquired ptosis	5 (1.06)
All complications	156 (33.3)

All patients were treated with topical corticosteroids in the active stage of disease along with mast cell stabilizers or antihistaminic eye drops for long-term prophylactic use. Topical 2% cyclosporine A was used in 23 patients (5%). Supratarsal injections of corticosteroid were used in 11 patients to treat severe non-responding disease. Two patients were treated with systemic corticosteroids for short period with tapering doses for 1 month in 1 patient and 3 months in other. None of the patients receiving supratarsal steroid injection had post-treatment glaucoma.

Discussion

Our study showed that VKC in the tropical Indian subcontinent is essentially similar to the pattern described in other tropical countries. The pattern here is predominantly mixed form of disease (72%) with significant number of patients having chronic perennial form (36%). Slightly higher propensity for VKC and its treatment-associated complications were seen. Persistent disease beyond 20 years of age was seen in increased number of patients (12%). To the best of our knowledge and PubMed search results, this is the largest series from this part of the world.

The highest incidence of patients was seen in the month of May, which corresponds to the hot dry weather in the southern part of India. VKC has seasonal exacerbations; however, chronic perennial form has been described and 36% of patients in our series had chronic perennial disease. Tuft *et al.*, noted differences between the clinical features of VKC in tropical and temperate countries and showed that VKC in tropical countries exhibits larger population with chronic perennial disease and lesser association with atopy.[6,10,11] In concordance to this, we noted that 36% of our patients exhibited chronic perennial disease and positive personal or family history of allergies was present in only 4.91% of patients; however, this is in contrast to the picture seen in the temperate zones as reported by Lambiasi *et al.*, and Bonini *et al.*, who found associated systemic allergies in 41.5-48.7% patients in different series.[4,12] Environmental factors may play a role in these regional differences associated with the same disease.

The prevalence of subtypes of VKC is different in various parts of the world. The multi centric study from Italy reported predominance (53.8%) of limbal presentation,[4] whereas Ukponmwan reported 82.6% cases with palpebral presentation in Nigeria.[6] In contrast, majority of our cases (71.8%) had a mixed presentation comprising of both limbal as well as palpebral involvement, followed by isolated palpebral involvement in 15.6% and limbal involvement in 12.6% of the patients. Perilimbalconjunctival pigmentation is a new clinical sign described in VKC.[13,14,15] In this series, perilimbalconjunctival pigmentation was documented in 52/468 (11%) of the patients. Rao *et al.*, described perilimbal pigmentation as a consistent finding in VKC. In our experience, we have often noted perilimbal pigmentation in VKC patients, but fewer patients in this study may be a reflection of the retrospective nature of the study and the lack of documentation of this relatively new sign of VKC.

Other visually significant complications seen in our series were corticosteroid-induced glaucoma and cataract. Corticosteroid-induced cataract was seen in 29 patients (6%), while glaucoma affected 18 patients (4%). Cataract was visually significant and required cataract extraction with posterior chamber intraocular lens implantation in 8 patients. Intractable glaucoma was treated with trabeculectomy in 6 patients and combined trabeculectomy with trabeculectomy in 1 patient. Bonini *et al.*,[12] described corticosteroid-induced glaucoma in 2.1% of patients in their series with no incidence of cataract, while Leonardi *et al.*, reported only 1 case of corticosteroid-induced cataract.[3]

In summary, this study has shown that VKC in India is essentially similar to the typical pattern of VKC seen in other tropical countries. Perennial pattern in large number of patients, persistent disease beyond the age of 20 years in 12% with adult onset disease in 3.5% of the patients and higher propensity for corticosteroid-induced cataract and glaucoma are certain findings seen in our study that one should consider during management of these cases.

REFERENCES

- Leonardi A, Secchi AG. Vernal keratoconjunctivitis. *IntOphthalmolClin.* 2003;43:41-58. | 2. Bonini S, Coassin M, Aronni S, Lambiasi A. Vernal keratoconjunctivitis. *Eye (Lond)* 2004;18:345-51. | 3. Leonardi A, Busca F, Motterle L, Cavarzeran F, Fregona IA, Plebani M, et al. Case series of 406 vernal keratoconjunctivitis patients: A demographic and epidemiological study. *ActaOphthalmol Scand.*2006;84:406-10. | 4. Lambiasi A, Minchiotti S, Leonardi A, Secchi AG, Rolando M, Calabria G, et al. Prospective, multicenter demographic and epidemiological study on vernal keratoconjunctivitis: A glimpse of ocular surface in Italian population. *Ophthalmic Epidemiol.* 2009;16:38-41. | 5. Tabarra KF. Ocular complications of vernal keratoconjunctivitis. *Can J Ophthalmol.* 1999;34:88-92. | 6. Ukponmwan CU. Vernal conjunctivitis in Nigerians: 109 consecutive cases. *Trop Doct.* 2003;33:242-5. | 7. Akinsola FB, Sonuga AT, Aribaba OT, Onakoya AO, Adefule-Ositelu AO. Vernal keratoconjunctivitis at Guinness Eye Centre, Luth (a five year study) *Nig Q J Hosp Med.* 2008;18:1-4. | 8. Sacchetti M, Baiardini I, Lambiasi A, Aronni S, Fassio O, Gramiccioni C, et al. Development and testing of the quality of life in children with vernal keratoconjunctivitis questionnaire. *Am J Ophthalmol.*2007;144:557-63. | 9. Bonini S, Sacchetti M, Mantelli F, Lambiasi A. Clinical grading of vernal keratoconjunctivitis. *Curr Opin Allergy Clin Immunol.* 2007;7:436-41. | 10. Shafiq I, Shaikh ZA. Clinical presentation of vernal keratoconjunctivitis (VKC): A Hospital based study. *J LiaquatUni Med Health Sci.* 2009;8:50-4. | 11. Tuft SJ, Cree IA, Woods M, Yorston D. Limbal vernal keratoconjunctivitis in the tropics. *Ophthalmology.* 1998;105:1489-93. | 12. Bonini S, Bonini S, Lambiasi A, Marchi S, Pasqualetti P, Zuccaro O, et al. Vernal keratoconjunctivitis revisited: A case series of 195 patients with long-term followup. *Ophthalmology.* 2000;107:1157-63. | 13. Rao SK, Padmanabhan P. Perilimbalconjunctival pigmentation in vernal keratoconjunctivitis: A new sign. *Cornea.* 2002;21:432. | 14. Rao SK, Meenakshi S, Srinivasan B, Baluswamy S. Perilimbal bulbar conjunctival pigmentation in vernal conjunctivitis: Prospective evaluation of a new clinical sign in an Indian population. *Cornea.*2004;23:356-9. | 15. Luk FO, Wong VW, Rao SK, Lam DS. Perilimbalconjunctival pigmentation in Chinese patients with vernal keratoconjunctivitis. *Eye (Lond)* 2008;22:1011-4. | 16. Sangwan VS, Jain V, Vemuganti GK, Murthy SI. Vernal keratoconjunctivitis with limbal stem cell deficiency. *Cornea.* 2011;30:491-6. | 17. Sangwan VS, Murthy SI, Vemuganti GK, Bansal AK, Gangopadhyay N, Rao GN. Cultivated corneal epithelial transplantation for severe ocular surface disease in vernal keratoconjunctivitis. *Cornea.*2005;24:426-30. |